Abstract Dopamine D4 receptor (D4R) mechanisms have been implicated in several psychiatric diseases, including schizophrenia, attention-deficit hyperactivity disorder (ADHD), and autism, which are characterized by cognitive deficits. The cellular mechanisms are poorly understood but impaired neuronal synchronization within cortical networks in the gamma frequency band has been proposed to contribute to these deficits. A D4R polymorphism was recently linked to variations in gamma power in both normal and ADHD subjects, and D4R activation was shown to enhance kainate-induced gamma oscillations in brain slices in vitro. The goal of this study was to investigate the effect of D4R activation on gamma oscillations in freely moving rats during natural behavior. Field potentials were recorded in the frontal, prefrontal, parietal, and occipital cortex and hippocampus. Gamma power was assessed before and after subcutaneous injection of a D4R agonist, A-412997, in several doses between 0.3 and 10.0 mg/kg. The experiments were also repeated in a neurodevelopmental model of schizophrenia, in which rats are prenatally treated with methylazoxymethanol (MAM). We found that the D4R agonist increased gamma power in all regions at short latency and lasted for *2 h, both in normal and MAM-treated rats. The effect was dose dependent indicated by the significant difference between the effects after 3 and 10 mg/kg in pair-wise comparison, whereas 0.3 and 1.0 mg/kg injections were ineffective. This study demonstrates the involvement of D4R in cortical gamma oscillations in vivo and identifies this receptor as potential target for pharmacological treatment of cognitive deficits.
Introduction
Starting from the initial characterization of the DRD4 gene by colleagues in 1991 (Van Tol et al. 1991) , the dopamine D4 receptor (D4R) has generated an exceptional level of interest for its potential relevance to schizophrenia. Later studies (Aguirre et al. 2007; Shi et al. 2008; Lung et al. 2009 ), including a meta-analysis (Allen et al. 2008) identified the DRD4 as a risk factor gene for schizophrenia. More recently, D4R related mechanisms and/or genetic variations have also been associated with other psychiatric diseases (Tarazi et al. 2004; Ptacek et al. 2011) , notably including autism (Deth et al. 2008; Gadow et al. 2010 ) and attention-deficit hyperactivity disorder (ADHD) (Lynn et al. 2005; McGough 2012) .
D4Rs are particularly enriched in fast firing parvalbumin-positive (PV?) interneurons (Mrzljak et al. 1996) , which play a critical role in neuronal network oscillations (Csicsvari et al. 2003; Sohal et al. 2009 ). Impairment of gamma oscillations, which are essential for a number of cognitive functions, such as perception, attention, working memory, etc., was demonstrated in diseases in which D4Rs are implicated, including in patients with autism (Hall et al. 2011 ) and schizophrenia (Uhlhaas and Singer 2012) and their first degree relatives (Hall et al. 2011; McFadden et al. 2012) . A DRD4 polymorphism was also linked to variations in gamma power (Demiralp et al. 2007 ) and D4R activation was shown to enhance kainate-induced gamma oscillations in hippocampal slices in vitro (Andersson et al. 2012a, b) . However, since gamma power might show opposite changes in vitro and in vivo under the same schizophrenia-relevant experimental interventions (Gandal et al. 2012; Kocsis et al. 2013) , the goal of this study was to determine whether D4R activation has an effect on gamma oscillations in vivo, in freely moving rats and whether the changes extend to neocortical networks, as well. We also studied the effect of D4R activation in a neurodevelopmental model of schizophrenia (Moore et al. 2006; Lodge et al. 2009 ), which recapitulates some of the characteristic alterations in gamma activity (Lodge et al. 2009; Kocsis et al. 2012 ) of human schizophrenia (Uhlhaas and Singer 2012) , but shows diminished capacity to generate druginduced gamma enhancement after NMDA receptor (NMDAR) blockade Phillips et al. 2012) .
Materials and methods
Experiments were performed on male Sprague-Dawley rats, (Charles River Laboratories, MA) treated in accordance with NIH guidelines. All procedures were approved by the Institutional Animal Care and Use Committees of Beth Israel Deaconess Medical Center. Electrophysiological recordings and drug injections followed the protocol described in our previous studies (Kittelberger et al. 2012; Kocsis 2012) . Rats were implanted with chronic EEG and EMG electrodes under ketamine-xylazine (70-80 and 10 mg/kg, respectively) anesthesia. Field potentials were recorded using surface screw electrodes placed at equidistant locations along a rostro-caudal axis, over the left frontal, parietal and occipital cortex (AP: 1.0, -2.5, -6.5 mm, Lat: 2.0, 2.5, 3.0 mm, respectively) and with fine wires in the prefrontal cortex (PFC) (AP: 3.2, Lat: 0.2, DV: 5.1 mm, on both sides) and hippocampus CA1 and DG regions (AP: 3.7, Lat: 2.2, DV: 2.5 and 3.5 mm, on the right side). Daily recordings started 7-10 days after surgery. The rats were placed in a recording box in the morning, and cortical and hippocampal EEG, and neck muscle EMG were continuously recorded for 24 h. Drug injection started after several days of baseline recording during which the return of normal sleep-wake cycle was verified, the rats accommodated to the recording environment, i.e. the box and the connecting cable, and the quality of recordings on different channels were evaluated and adjusted. In the following recording days, between 4 and 5 h after the start of control recording, during the light phase of the day, saline or the D4R agonist A-412997 (Tocris) was injected subcutaneously in one of the following doses: 10.0 (n = 9), 3.0 (n = 9), 1.0 (n = 3), 0.3 (n = 2) mg/kg. Saline was used as vehicle control in all rats (n = 10). Each rat received multiple injections, the order of drug doses varied randomly and at least 2 days were allowed between consecutive injections for washout. A-412997 is a full D4R agonist with high affinity for both rat and human D4R (Ki = 12.1 and 7.9 nM, respectively) .
Treatment with methylazoxymethanol acetate (MAM) followed previously developed and commonly used protocols (Moore et al. 2006; Lodge et al. 2009; Kocsis et al. 2012; Phillips et al. 2012) . Pregnant rats were obtained on gestational day 10 and housed individually. On GD17, rats were injected intraperitoneally with MAM at a dose of 22 mg/kg, or saline. Male pups were weaned 30 days after birth and housed in pairs under standard conditions. Experiments were carried out when the animals were 3-6 months old.
EEG signals were filtered between 0.1 and 100 Hz and sampled at 256 Hz. Power spectral density (PSD) was calculated using fast Fourier transform on consecutive 4 s long windows. Gamma oscillations were assessed using the average spectral power in two frequency bands, the first to cover all changes in the spectrum (20-65 Hz, see ''Results'' for details) and second to limit the evaluation to gamma frequencies . Two 20 min-long preinjection segments, representing non-active and active behaviors, were selected and compared with the first 20 min of post-injection recording. For presenting the time course of fluctuations in gamma band power (Figs. 2a, 3a) , gamma activity was averaged over 5 min-long periods and normalized using a 1 h-long quiet episode before injection. Student's t test and two-way ANOVA with post hoc Bonferroni pair-wise comparisons were used for statistical analyses.
Results
The spectral composition of EEG signals after D4R activation was compared with two types of pre-injection control EEG patterns. First, a *20 min segment of quiet waking/slow wave sleep was selected in which there was no EMG activity, no theta activity in the hippocampal EEG, and frontal cortex EEG was dominated by irregular delta band activity. The PSD of these segments (blue traces in Fig. 1a, b) showed the well-known 1/f-like characteristics in the frequency range between *15 and 90 Hz, i.e. above the characteristic slow oscillatory components and below the filter cut-off frequency of 100 Hz (Wright et al. 2001) . The second segment (*20 min long) was selected from a period when the rats showed active motor behavior, indicated by high EMG activity and an EEG pattern characteristic for high vigilance states. The PSD of these EEG segments (black traces in Fig. 2a , b) contained two linear components on the log-log plot, both showing 1/f-like decline of power with increasing frequency, but at different rates. The ''knee point'', at which the slope of the spectra changed to a steeper decline, differed from one cortical area to the next, between 44 and 47 Hz in the frontal, parietal and hippocampal EEG, but at somewhat higher frequencies in occipital cortex (52 ± 3 Hz) and PFC (59 ± 1 Hz) (see Table S1 ). The two control PSDs (see blue and black lines in Fig. 1a , b) crossed between 21 and 24 Hz in all recording locations (Table S1 ). Activation of D4Rs increased spectral power (red traces in Fig. 1a , b) between these two characteristic frequencies (see arrows); outside of this range, slopes of the 1/f-like activity were similar to the active waking control EEG. Thus, D4R agonist primarily affected gamma frequencies in a wide gamma range, and the effect somewhat extended into the upper part of the beta band. There was no change at lower beta frequencies and the peak of enhanced power always fell into the gamma band, i.e. above 30 Hz, indicating a primary involvement of gamma oscillations. Spectral analysis included the 20-65 Hz range to cover the entire range of enhanced power, and the conclusions regarding gamma activity were also verified by repeating the analysis in the 30-65 Hz range. Figure 2a shows the temporal variations of gamma band power, along with integrated EMG activity, in the first 11 h of a representative experiment in which the D4R agonist A-412997 was injected in the highest dose (10 mg/kg), after 5 h of control recording. At the beginning of the experiment, after the rats were tethered and moved from their home cage in the recording box, they engaged in active motor behavior for the first 20-90 min (see high EMG activity in the first 70 min in Fig. 1 interrupted by rapid eye movement sleep and short episodes of active waking. After injection, the rats were again awake for a period which lasted from 31 ± 3 min after vehicle, to 112 ± 10 min after highest dose of A-412997 (see Table S2 ). Longer periods of active waking appeared later during the day (e.g. 9.5-10.5 h in Fig. 2a ) and more during the night (data not shown). Motor activity was accompanied by a 26 ± 7 and 21 ± 4 % (in frontal cortex and PFC respectively) increase (p \ 0.05) in gamma band power, but this increase was significantly exceeded by a lasting gamma enhancement induced by the D4R agonist (*75-100 % in the example in Fig. 1a) . For statistical comparison, pre-and post-injection gamma power was calculated in the 20-65 Hz (Fig. 2b, c) , as well as in the 30-65 Hz frequency range, which gave similar results. Since the rats were awake and showed motor activity after drug injections, the active control segment served as pre-injection control. After injection of the D4R agonist at the highest dose, gamma power increased in each region (frontal cortex: 49 ± 15 %, PFC: 40 ± 11 %, parietal: 38 ± 18 %, occipital: 47 ± 7 %, hippocampus CA1: 19 ± 6 %) (Fig. 2b ) (see Fig. S1 and Table S3 for the effect after other doses). The gamma increase reached significance (t test, p \ 0.05) in the frontal cortex and PFC and showed a strong tendency for increase (0.05 \ p \ 0.1) in the remaining locations. Twoway ANOVA confirmed a significant drug effect (F[4,89] = 15.31, p = 2.4E-9, statistical power at alpha = 0.05:1), whereas the difference between cortical areas was close to a significant level (F[5,89] = 2.32, p = 0.0507). Post-hoc Bonferroni test showed significant differences in all pair-wise dose comparisons, except for pairs composed of saline, and the lower doses (0.1 and 0.3 mg/kg). The effect was dose-dependent indicated by the significant difference between the effects after 3 and 10 mg/kg in pair-wise comparison, whereas 0.3 and 1.0 mg/kg injections were ineffective (Fig. 2c) . The results were similar and led to identical statistical conclusions (Table S4 ) when the analysis was limited to frequencies above 30 Hz.
D4R activation also elicited a massive enhancement of gamma band power in MAM-treated rats (Fig. 3a) . Baseline power was higher in MAM-treated rats than in normal controls in the PFC and occipital cortex (t test, p \ 0.05). Drug-induced increase in gamma activity was highest in PFC where it reached 81 ± 19 % (t test, p = 0.004), after injecting 10 mg/kg A412997. In other areas, gamma increased between 38 and 52 % (Fig. 3b ) (see Table S3 for 20-65 Hz and S4 for 30-65 Hz). The effect was dosedependent (Fig. 3c) significant drug effect (F[2,57] = 23.22, p = 7.3E-8, statistical power at alpha = 0.05:1) and a post hoc Bonferroni test showed significant differences in all pair-wise comparisons, between saline, 3 and 10 mg/kg A-412997. D4R agonist effect on gamma activity in MAM-rats was generally stronger than in normal rats (two-way ANOVA F[1,121] = 5.27, p = 0.02), although in pair-wise comparisons the group differences only came close to significant level in the PFC (t test, p = 0.056). The character of gamma band PSD also differed between the two groups. In MAM-treated rats, there were prominent gamma peaks at 51 ± 1 Hz in pre-injection active control EEG recordings which was most remarkable in the PFC in all rats (Fig. 4b) . After injection of D4R agonist, the peak gamma frequency in PFC decreased (46 ± 2 Hz; in Fig. 4) , while its amplitude increased (Fig. 3b) . In other areas (e.g. occipital cortex in Fig. 4a ), gamma enhancement was more uniform over the entire gamma band.
Discussion
A few years after the discovery of high affinity binding of clozapine to the D4R (Van Tol et al. 1991) and altered D4R expression in postmortem schizophrenic brains (Seeman et al. 1993) , the original enthusiasm regarding D4R weakened when highly selective antagonists were found ineffective as antipsychotic agents in neuroleptic-sensitive patients (Kramer et al. 1997 ) and failed to improve scores on the positive and negative symptom scales for schizophrenic patients (Corrigan et al. 2004 ). The present findings, along with those in a recent in vitro study (Andersson et al. 2012a, b) , suggest, however, that D4Rs may be involved in other aspects, namely cognitive impairment, in schizophrenia and possibly other psychiatric diseases, such as autism and ADHD (Deth 2003; Tarazi et al. 2004; Deth et al. 2008 ). These conditions share common features including abnormal gamma oscillations (Yordanova et al. 2001; Hall et al. 2011; McFadden et al. 2012; Uhlhaas and Singer 2012) , which are essential for a variety of cognitive functions. Thus, the current findings of a robust effect of a D4R agonist on gamma activity in different cortical areas, including the PFC, of freely moving rats, and in hippocampal slices in vitro, raises the potential of targeting the D4R for the treatment of cognitive symptoms in these disorders. D4R agonists including A-412997, was effective in restoring cognitive deficits in specific tasks in preclinical studies (Browman et al. 2005; Woolley et al. 2008) .
A B C Fig. 3 Effect of D4R agonist on gamma band power in cortical EEG in MAM-treated rats. a Time course of gamma power (20-65 Hz) in the occipital and prefrontal cortex in a representative experiment, along with neck muscle EMG. A-412997 was injected in a dose of 10 mg/kg. Power is expressed as percent change relative to a 1 h quiet period with no muscle activity between hours 2 and 3. b Increase in gamma band activity postinjection, relative to preinjection level in active waking in different areas of cortex and hippocampus. c Dose-response effect.
Relationship between dose of A-412997 and increase in gamma activity in the frontal and prefrontal cortex of the group of MAM-treated rats (n = 4; *p \ 0.05;
There is a rapidly growing interest in altered gamma oscillations in schizophrenia, fueled by a shift in understanding the core deficits from psychotic to negative symptoms and to cognitive deficits. The latter are unaffected by antipsychotic drugs but have stronger predictive value than the severity of positive symptoms (Tamminga et al. 1998) . Abnormal cortical oscillations are commonly associated with structural changes of interneuron networks such as decreased expression of GAD67 and PV in GABAergic cells, which is one of the most reliable postmortem findings in schizophrenic brains (Woo et al. 1997) . The effect of D4R activation on gamma oscillation is most likely mediated by an action on this type of neurons, which are particularly enriched with D4R. Indeed, Anderson and colleagues (Andersson et al. 2012a ) provided evidence of increased synchronization of fast firing interneurons and IPSPs in pyramidal cells with gamma field potentials after D4R activation. They also proposed that the D4R effect involves NMDARs, as blockade with AP5 significantly reduced D4R agonist-induced gamma enhancement. Although the effect of NMDAR antagonists on gamma oscillations in vivo, both in rodents (Pinault 2008) and human (Hong et al. 2010) , is diametrically different from that in vitro (Cunningham et al. 2006; Roopun et al. 2008 ), our present findings are not inconsistent with a joint action of the two receptors on the same interneurons. D4R activation was previously shown to reduce NMDAR-mediated current and EPSPs (Wang et al. 2003) , which may lead to enhanced gamma activity, similar to that after NMDAR blockade or genetic ablation of NMDAR in PV? interneurons (Korotkova et al. 2010; Carlen et al. 2012) .
Since research focusing on altered neuronal network dynamics in schizophrenia is primarily conducted in the framework of the NMDAR hypofunction hypothesis, it is worthwhile to compare the D4R gamma effect with that induced by NMDAR antagonists. In freely moving rats, both D4R activation and NMDAR antagonism lead to similar, steady enhancements of gamma activity, which appear at short latency, last for several hours, and are associated with active waking behavior and high EMG activity. However, the spectral characteristics of gamma activity differ between the two conditions. In the present study, gamma enhancement after D4R activation in normal rats was limited to the frequency band marked by the 1/flike segment of the spectrum that normally appears during high vigilance states (Wright et al. 2001; Buzsaki 2006) . In contrast, enhanced gamma activity after NMDAR blockade showed two prominent peaks, one between 30 and 50 Hz and the other between 60 and 70 Hz, i.e. outside of this range (Kocsis 2012) . Interestingly, when NMDR blockade A B C D Fig. 4 Spectral characteristics of the changes in EEG induced by D4R activation in a MAMtreated rat. a, b Power density spectra of field potential recordings in the occipital (a) and prefrontal (b) cortex, in pre-injection quiet waking/ slow-wave sleep (blue no-MOV), and active waking (black ctrl-MOV) and after drug injection (10 mg/kg A-412997) (red) between 15 and 90 Hz. Note 1/f-like PSD patterns associated with non-active states (blue) and two-segment composite PSDs in active waking (black) with a ''knee'' point at *60 Hz, with a gamma peak at *55 Hz riding on the top; note also crossing of the two spectra at *20 Hz (marked by arrows). Spectral power increased between these two characteristic frequencies. c, d Difference between PSD in active and quiet pre-injection control episodes (black ctrl) and between post-injection EEG and quiet pre-injection control (red) selectively targeted NR2A subunit-containing receptors, gamma enhancement was dominant in the lower gamma range (Kocsis 2012), i.e. similar to that after D4R activation. This specific type of NMDR is predominantly expressed in PV? interneurons and is thus most likely co-localized with D4Rs (Xi et al. 2009 ).
There was also a discrepancy between the gamma responses to NMDAR blockade vs. D4R activation in MAM-treated rats. This neurodevelopmental model was shown to recapitulate the essential feature of human schizophrenia (Moore et al. 2006; Lodge et al. 2009 ), namely, an initial damage carried from before birth leading to pathologic symptoms which only manifest after puberty (Le Pen et al. 2006) . It also showed a gamma deficit during schizophrenia-relevant cognitive tasks (Lodge et al. 2009) , and increased background gamma activity , matching the common pattern of gamma alterations seen in other rodent models and in human schizophrenia patients (Gandal et al. 2012; Kocsis et al. 2013) . NMDAR antagonists elicit an exaggerated hyperlocomotion response in MAM-treated rats, but the concomitant gamma enhancement is weaker than in normal rats Phillips et al. 2012) . This is different from the finding of this study, in that MAM-treated rats showed no deficit in D4R-induced gamma enhancement; the reaction in the PFC was even larger than in the control group. The exact mechanism of NMDAR antagonist-induced gamma impairment remains unknown, but it is commonly associated with disfacilitation of PV? interneurons, which show abnormalities such as low GAD67 and PV expression in schizophrenia and in different animal models, including the MAM model. D4R expression has not been studied in animal models, but was shown to be increased in schizophrenic patients (Seeman et al. 1993) . Since D4Rs are predominantly expressed in interneurons (Mrzljak et al. 1996) , their increase might represent a compensatory reaction to interneuron dysfunction and might explain the different reactions of oscillatory networks to the manipulation of these receptors.
